For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Adalimumab - Inflammatory bowel disease
PAD Profile : Adalimumab - Inflammatory bowel disease Important
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Azathioprine
- Infliximab
- Mercaptopurine
- Ciclosporin
- Golimumab
- Vedolizumab
- Allopurinol
- Balsalazide sodium
- Prednisolone
- Budesonide
- Tofacitinib
- Methotrexate
- Mesalazine (Systemic)
- Filgotinib
- Sulfasalazine
- Upadacitinib
- Risankizumab
- Olsalazine sodium
Other Indications
- Ankylosing spondylitis
- Psoriasis
- Psoriatic arthritis
- Rheumatoid arthritis
- Non-radiographic axial spondyloarthritis
- Behcet's syndrome
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway.
ULCERATIVE COLITIS:
The PCN recommends adalimumab dose escalation (40mg weekly OR 80mg fortnightly) in patients with moderately to severely active ulcerative colitis for a 12 week treatment course to recapture response.
Patients must return to standard dosing (40mg fortnightly) after the 12 week course has been completed.
If the patient loses response to the standard dosing within a short time period (1 month) then the provider can apply for funding to return to the escalated dose (40mg weekly OR 80mg fortnightly).
Gastroenterology specialists will be required to repeat the 12 week course if the patient starts to lose response after 1 month of standard dosing (40mg weekly).
Adalimumab is a payment by results excluded drug and will be considered RED on the traffic light system.
Gastroenterology specialists will be required to complete blueteq initiation and continuation forms for the commissioners.
ULCERATIVE COLITIS:
The PCN recommends the sequential use of TNF alpha inhibitors (adalimumab, infliximab or golimumab) in patients with moderately to severely active ulcerative colitis prior to a switch to vedolizumab.
Adalimumab, Infliximab and Golimumab are payment by results excluded drugs and will be considered RED on the traffic light system.
Gastroenterology specialists will be required to complete blueteq initiation and continuation forms for the commissioners.
The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products
Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.